cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.27720957
title: Spinal cord stimulation in a patient with an implantable cardioverter defibrillator for managing chronic chest pain: a case report and literature review

description: The simultaneous use of spinal cord stimulation (SCS) and an implantable cardioverter-defibrillator (ICD) is safe and effective in selected patients with refractory chest pain. Our case highlights successful pain management with SCS without compromising ICD function. Careful patient selection, low device settings, and ongoing monitoring are crucial for achieving optimal outcomes. <b>What is this article about?</b> Spinal cord stimulators are used to treat pain that won’t go away. However, some patients also have implantable electronic devices, which makes them worry that the two devices may not work well together. This article describes a case in which both devices were used and presents a literature review regarding the possible interactions between these two devices. <b>What were the results?</b> Spinal cord stimulation is a safe and efficient treatment for persistent refractory pain in patients using implantable cardiac electronic devices. <b>What do the results means?</b> These results suggest that spinal cord stimulation is a safe and effective treatment for chronic refractory pain in patients using cardiac implantable electronic devices.
DOI: 10.6084/m9.figshare.27720957.v1
title: Spinal cord stimulation in a patient with an implantable cardioverter defibrillator for managing chronic chest pain: a case report and literature review

description: The simultaneous use of spinal cord stimulation (SCS) and an implantable cardioverter-defibrillator (ICD) is safe and effective in selected patients with refractory chest pain. Our case highlights successful pain management with SCS without compromising ICD function. Careful patient selection, low device settings, and ongoing monitoring are crucial for achieving optimal outcomes. <b>What is this article about?</b> Spinal cord stimulators are used to treat pain that won’t go away. However, some patients also have implantable electronic devices, which makes them worry that the two devices may not work well together. This article describes a case in which both devices were used and presents a literature review regarding the possible interactions between these two devices. <b>What were the results?</b> Spinal cord stimulation is a safe and efficient treatment for persistent refractory pain in patients using implantable cardiac electronic devices. <b>What do the results means?</b> These results suggest that spinal cord stimulation is a safe and effective treatment for chronic refractory pain in patients using cardiac implantable electronic devices.
DOI: 10.6084/m9.figshare.27910204
title: The efficacy of topical 8% capsaicin patches for the treatment of postsurgical neuropathic pain: a systematic review

description: To investigate the benefits of topical 8% capsaicin patches for the decrease of postsurgical neuropathic pain level and area. A systematic review with pooled analysis was conducted utilizing the PRISMA 2020 guidelines. Five commonly used databases were employed utilizing a search string made from MeSH terms and boolean operators. Retrieved articles were then subjected to title and abstract appraisal, followed by full-text appraisal by two independent reviewers and an adjudicator to break ties. A total of 127 articles were retrieved from five commonly used databases. Of the 127 articles, 20 were subjected to full-text appraisal, with 12 remaining for inclusion. Due to a heterogeneity greater than the 50% threshold provided by Cochrane, a random-effects pooled-analysis was conducted in lieu of meta-analysis. The random-effects pooled-analysis denotes an overall Cohen’s d of 1.09 (95% CI: 0.58–1.56; <i>p</i> &lt; 0.001). All studies that investigated neuropathic pain area denote a decrease in pain size, with some denoting a continued reduction with subsequent application. Further larger randomized-controlled trials are required to strengthen the position of topical capsaicin patches in the physician’s armamentarium. www.crd.york.ac.uk/prospero identifier is CRD42024542508. Capsaicin, a common substance that gives pepper plants their spice, can be used to help treat nerve pain when concentrated into an 8% patch. Eight percent capsaicin patches offer a non-pill-based alternative for pain relief, which may not be responding to other forms of treatment. When an individual undergoes surgery, they are often left with nerve pain around the location of the procedure or scar. Post-surgical nerve pain is often located in sensitive areas that are difficult to treat, and our results indicate that adequate treatment combining topical numbing medications followed by 8% capsaicin patches can provide significant and sustained relief (lasting up to a few months following the treatment). In addition to reducing the severity of post-surgical nerve pain, capsaicin can also shrink the overall size of the area of nerve pain. Although this treatment is newer compared to more commonly used medicines, it offers significant promise for helping relieve nerve pain in patients who have undergone various types of surgery across various parts of their bodies. Further studies are required to determine the exact amount of benefit this treatment can provide when compared to commonly used medications and therapies.
DOI: 10.6084/m9.figshare.27910204.v1
title: The efficacy of topical 8% capsaicin patches for the treatment of postsurgical neuropathic pain: a systematic review

description: To investigate the benefits of topical 8% capsaicin patches for the decrease of postsurgical neuropathic pain level and area. A systematic review with pooled analysis was conducted utilizing the PRISMA 2020 guidelines. Five commonly used databases were employed utilizing a search string made from MeSH terms and boolean operators. Retrieved articles were then subjected to title and abstract appraisal, followed by full-text appraisal by two independent reviewers and an adjudicator to break ties. A total of 127 articles were retrieved from five commonly used databases. Of the 127 articles, 20 were subjected to full-text appraisal, with 12 remaining for inclusion. Due to a heterogeneity greater than the 50% threshold provided by Cochrane, a random-effects pooled-analysis was conducted in lieu of meta-analysis. The random-effects pooled-analysis denotes an overall Cohen’s d of 1.09 (95% CI: 0.58–1.56; <i>p</i> &lt; 0.001). All studies that investigated neuropathic pain area denote a decrease in pain size, with some denoting a continued reduction with subsequent application. Further larger randomized-controlled trials are required to strengthen the position of topical capsaicin patches in the physician’s armamentarium. www.crd.york.ac.uk/prospero identifier is CRD42024542508. Capsaicin, a common substance that gives pepper plants their spice, can be used to help treat nerve pain when concentrated into an 8% patch. Eight percent capsaicin patches offer a non-pill-based alternative for pain relief, which may not be responding to other forms of treatment. When an individual undergoes surgery, they are often left with nerve pain around the location of the procedure or scar. Post-surgical nerve pain is often located in sensitive areas that are difficult to treat, and our results indicate that adequate treatment combining topical numbing medications followed by 8% capsaicin patches can provide significant and sustained relief (lasting up to a few months following the treatment). In addition to reducing the severity of post-surgical nerve pain, capsaicin can also shrink the overall size of the area of nerve pain. Although this treatment is newer compared to more commonly used medicines, it offers significant promise for helping relieve nerve pain in patients who have undergone various types of surgery across various parts of their bodies. Further studies are required to determine the exact amount of benefit this treatment can provide when compared to commonly used medications and therapies.
DOI: 10.6084/m9.figshare.27282650
title: Combatting opioid misuse, overuse and abuse: a systematic review of pharmacists' services and outcomes

description: <b>Aim:</b> To examine the range of services pharmacists provide and their impact on patient outcomes, harm reduction, and appropriate opioid use. <b>Methods:</b> Six databases were searched (MEDLINE, EMBASE, Scopus, PsycINFO, CENTRAL and Cochrane Methodology Register) from inception to March 2023. The protocol was registered in PROSPERO (CRD42023401895). <b>Results:</b> Twenty-nine studies identified five key areas of pharmacist interventions in opioid management—naloxone programs and opioid de-escalation, patient and primary healthcare providers' education and motivational interview, prescription monitoring and opioid risk screening, clinical pharmacy interventions (pharmacotherapy, medication review, prescribing, adherence monitoring), and collaborative healthcare approaches to promote optimal opioid use. Outcomes assessment indicated harm reduction, improved safety, increased non-opioid analgesic use, decreased opioid consumption, and enhanced pain management. <b>Conclusion:</b> This review underscores pharmacists' vital role in tackling opioid misuse, overuse and abuse, providing a foundation for evidence-based policies to minimize harm and promote optimal opioid use. This study investigated the scope of services provided by pharmacists and their impact on patient outcomes, harm reduction, and appropriate opioid utilization. This review identified five key areas of contributions made by pharmacists in rational opioid prescribing and use and demonstrated a positive impact on core outcomes. These results emphasize the critical role of pharmacists in addressing the complex issues surrounding opioid use, misuse and abuse. Pharmacists' services significantly reduce opioid-related harm, including through naloxone programs and opioid de-escalation. Educational interventions by pharmacists improve patient adherence and knowledge regarding opioid safety. Collaborative care approaches between pharmacists and other healthcare professionals enhance patient outcomes and reduce opioid misuse. There is a critical gap in addressing misuse of other opioid substances beyond naloxone.
DOI: 10.6084/m9.figshare.27282650.v2
title: Combatting opioid misuse, overuse and abuse: a systematic review of pharmacists' services and outcomes

description: <b>Aim:</b> To examine the range of services pharmacists provide and their impact on patient outcomes, harm reduction, and appropriate opioid use. <b>Methods:</b> Six databases were searched (MEDLINE, EMBASE, Scopus, PsycINFO, CENTRAL and Cochrane Methodology Register) from inception to March 2023. The protocol was registered in PROSPERO (CRD42023401895). <b>Results:</b> Twenty-nine studies identified five key areas of pharmacist interventions in opioid management—naloxone programs and opioid de-escalation, patient and primary healthcare providers' education and motivational interview, prescription monitoring and opioid risk screening, clinical pharmacy interventions (pharmacotherapy, medication review, prescribing, adherence monitoring), and collaborative healthcare approaches to promote optimal opioid use. Outcomes assessment indicated harm reduction, improved safety, increased non-opioid analgesic use, decreased opioid consumption, and enhanced pain management. <b>Conclusion:</b> This review underscores pharmacists' vital role in tackling opioid misuse, overuse and abuse, providing a foundation for evidence-based policies to minimize harm and promote optimal opioid use. This study investigated the scope of services provided by pharmacists and their impact on patient outcomes, harm reduction, and appropriate opioid utilization. This review identified five key areas of contributions made by pharmacists in rational opioid prescribing and use and demonstrated a positive impact on core outcomes. These results emphasize the critical role of pharmacists in addressing the complex issues surrounding opioid use, misuse and abuse. Pharmacists' services significantly reduce opioid-related harm, including through naloxone programs and opioid de-escalation. Educational interventions by pharmacists improve patient adherence and knowledge regarding opioid safety. Collaborative care approaches between pharmacists and other healthcare professionals enhance patient outcomes and reduce opioid misuse. There is a critical gap in addressing misuse of other opioid substances beyond naloxone.
DOI: 10.6084/m9.figshare.27282650.v1
title: Combatting opioid misuse, overuse and abuse: a systematic review of pharmacists' services and outcomes

description: <b>Aim:</b> To examine the range of services pharmacists provide and their impact on patient outcomes, harm reduction, and appropriate opioid use. <b>Methods:</b> Six databases were searched (MEDLINE, EMBASE, Scopus, PsycINFO, CENTRAL and Cochrane Methodology Register) from inception to March 2023. The protocol was registered in PROSPERO (CRD42023401895). <b>Results:</b> Twenty-nine studies identified five key areas of pharmacist interventions in opioid management—naloxone programs and opioid de-escalation, patient and primary healthcare providers' education and motivational interview, prescription monitoring and opioid risk screening, clinical pharmacy interventions (pharmacotherapy, medication review, prescribing, adherence monitoring), and collaborative healthcare approaches to promote optimal opioid use. Outcomes assessment indicated harm reduction, improved safety, increased non-opioid analgesic use, decreased opioid consumption, and enhanced pain management. <b>Conclusion:</b> This review underscores pharmacists' vital role in tackling opioid misuse, overuse and abuse, providing a foundation for evidence-based policies to minimize harm and promote optimal opioid use. This study investigated the scope of services provided by pharmacists and their impact on patient outcomes, harm reduction, and appropriate opioid utilization. This review identified five key areas of contributions made by pharmacists in rational opioid prescribing and use and demonstrated a positive impact on core outcomes. These results emphasize the critical role of pharmacists in addressing the complex issues surrounding opioid use, misuse and abuse. Pharmacists' services significantly reduce opioid-related harm, including through naloxone programs and opioid de-escalation. Educational interventions by pharmacists improve patient adherence and knowledge regarding opioid safety. Collaborative care approaches between pharmacists and other healthcare professionals enhance patient outcomes and reduce opioid misuse. There is a critical gap in addressing misuse of other opioid substances beyond naloxone.
DOI: 10.5281/zenodo.10621274
title: Simulation output data for: "Promising regions for detecting the overturning circulation in Atlantic Pa/Th: a model-data comparison"

description: Version 2.0.0: used for publication.Overview of doi's:



manuscript preprint: https://doi.org/10.22541/essoar.170898721.10752966/v1

code (analysis and figures): https://doi.org/10.5281/zenodo.14791063 

simulation output (dataset): https://doi.org/10.5281/zenodo.10622404


This dataset contains the output of model simulations used in the study: 

Scheen, Jeemijn and Lippold, Jörg and Pöppelmeier, Frerk and Süfke, Finn and Stocker, Thomas F., "Promising regions for detecting the overturning circulation in Atlantic Pa/Th: a model-data comparison", Paleoceanography and Paleoclimatology, 2025 

All figures can be reproduced when combining this dataset with the analysis code. It is not necessary to understand the below.

 

Filenames have the following forms:



RUNNAME.0001765_timeseries_ave.nc contains simulation output for variables that are timeseries (1-dimensional) of a run RUNNAME.

RUNNAME.0001765_full_ave.nc contains simulation output for more-dimensional variables (lat/lon/z/time) of a run RUNNAME.

RUNNAME.out (inside 1_log_outfiles.zip) not used for figures; provides additional information that is printed during simulation.

RUNNAME.*.parameter (inside 1_parameterfiles.zip)not used for figures; provides all parameter settings used in the simulation. Most relevant are RUNNAME.main.parameter (general settings) and RUNNAME.bgc.parameter (settings of biogeochemical module including Pa and Th). Freshwater forcings are defined in RUNNAME.fw.parameter & RUNNAME.forcing.parameter.

weak_amoc010sv.dat & weak_amoc015sv.dat & weak_amoc020sv.datnot used for figures; are the 3 forcing files for North Atlantic freshwater that result in an AMOC of ~14Sv, ~11Sv respectively ~9Sv. The model interpolates linearly between time steps given in the .dat file; the first simulation year is called 1765 in the model. 

1_README.txtContains the same information as here + a list to match RUNNAME to the (clearer) runnames used in the manuscript.


Here, RUNNAME corresponds to the original runname at time of simulation (exactly 10 characters). They can be matched to the (clearer) runnames used in the manuscript via the list given in 1_README.txt.

In addition to the 27 runs used in the manuscript, 4 extra runs are shared:



SPIN3INTEL: the spinup from which most runs started (an intel fortran compiler is used for all runs).

WEAK010SV: a freshwater forcing of 0.10 Sv is turned on and the AMOC is run into its new equilibrium in this simulation. All _14Sv runs start from this run. 

WEAK015SV: idem for 0.15 Sv. All _11Sv runs start from this run. 

WEAK020SV: idem for 0.20 Sv. All _9Sv runs start from this run.
DOI: 10.5281/zenodo.14791063
title: Simulation output data for: "Promising regions for detecting the overturning circulation in Atlantic Pa/Th: a model-data comparison"

description: Version 2.0.0: used for publication.Overview of doi's:



manuscript preprint: https://doi.org/10.22541/essoar.170898721.10752966/v1

code (analysis and figures): https://doi.org/10.5281/zenodo.14791063 

simulation output (dataset): https://doi.org/10.5281/zenodo.10622404


This dataset contains the output of model simulations used in the study: 

Scheen, Jeemijn and Lippold, Jörg and Pöppelmeier, Frerk and Süfke, Finn and Stocker, Thomas F., "Promising regions for detecting the overturning circulation in Atlantic Pa/Th: a model-data comparison", Paleoceanography and Paleoclimatology, 2025 

All figures can be reproduced when combining this dataset with the analysis code. It is not necessary to understand the below.

 

Filenames have the following forms:



RUNNAME.0001765_timeseries_ave.nc contains simulation output for variables that are timeseries (1-dimensional) of a run RUNNAME.

RUNNAME.0001765_full_ave.nc contains simulation output for more-dimensional variables (lat/lon/z/time) of a run RUNNAME.

RUNNAME.out (inside 1_log_outfiles.zip) not used for figures; provides additional information that is printed during simulation.

RUNNAME.*.parameter (inside 1_parameterfiles.zip)not used for figures; provides all parameter settings used in the simulation. Most relevant are RUNNAME.main.parameter (general settings) and RUNNAME.bgc.parameter (settings of biogeochemical module including Pa and Th). Freshwater forcings are defined in RUNNAME.fw.parameter & RUNNAME.forcing.parameter.

weak_amoc010sv.dat & weak_amoc015sv.dat & weak_amoc020sv.datnot used for figures; are the 3 forcing files for North Atlantic freshwater that result in an AMOC of ~14Sv, ~11Sv respectively ~9Sv. The model interpolates linearly between time steps given in the .dat file; the first simulation year is called 1765 in the model. 

1_README.txtContains the same information as here + a list to match RUNNAME to the (clearer) runnames used in the manuscript.


Here, RUNNAME corresponds to the original runname at time of simulation (exactly 10 characters). They can be matched to the (clearer) runnames used in the manuscript via the list given in 1_README.txt.

In addition to the 27 runs used in the manuscript, 4 extra runs are shared:



SPIN3INTEL: the spinup from which most runs started (an intel fortran compiler is used for all runs).

WEAK010SV: a freshwater forcing of 0.10 Sv is turned on and the AMOC is run into its new equilibrium in this simulation. All _14Sv runs start from this run. 

WEAK015SV: idem for 0.15 Sv. All _11Sv runs start from this run. 

WEAK020SV: idem for 0.20 Sv. All _9Sv runs start from this run.
DOI: 10.60656/0f630ee4c1bf48c4
title: Custom collection of model data from Palaiseau between 17 Oct 2024 and 10 Feb 2025
DOI: 10.18150/x0hp6o
title: Aligned silver nanowires for plasmonically-enhanced fluorescence detection of photoactive proteins in wet and dry environment

description: Data for the manuscript entitled "Aligned silver nanowires for plasmonically-enhanced fluorescence detection of photoactive proteins in wet and dry environment"
DOI: 10.15468/dl.b9jx9u
title: Occurrence Download

description: A dataset containing 82 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Solanum alphonsi Dunal"
 ]
}

 The dataset includes 82 records from 24 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0023279-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.egwf5h
title: Occurrence Download

description: A dataset containing 5 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Colombia",
 "Geometry POLYGON((-72.47864 2.56619,-72.60855 2.61042,-72.64724 2.61318,-72.69976 2.61318,-72.72464 2.58001,-72.78623 2.57417,-72.81861 2.60765,-72.84625 2.58554,-72.9347 2.56343,-73.0038 2.50262,-73.01762 2.41417,-72.97893 2.33954,-72.802 2.28111,-72.697 2.32296,-72.37913 2.35613,-72.47864 2.56619))",
 "OccurrenceStatus is Present",
 "TaxonKey is Podocnemis unifilis Troschel, 1848",
 "Year 2014-2024"
 ]
}

 The dataset includes 5 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0023285-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.d5c3hw
title: Occurrence Download

description: A dataset containing 836 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Somniosus microcephalus (Bloch & Schneider, 1801)"
 ]
}

 The dataset includes 836 records from 55 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0023282-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5517/ccdc.csd.cc2k04g6
title: CCDC 2353627: Experimental Crystal Structure Determination

description: Related Article: Nuo Li, Qiuyan Tan, Qing Wang, Kun Huang, Xueli Yang, Lijuan Liang|2025|J.Mol.Struct.|1329|141393|doi:10.1016/j.molstruc.2025.141393
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2knrff
title: CCDC 2373435: Experimental Crystal Structure Determination

description: Related Article: Xueling Liu, Chen Si, Junjie Xu, Hui Sun, Jie Li, Qiuxia Han|2025|Inorg.Chem.|64|1263|doi:10.1021/acs.inorgchem.4c03219
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.